Safety Profile of Dapagliflozin Among Patients With Type 2 Diabetes Hospitalized With COVID-19

Name: Safety Profile of Dapagliflozin Among Patients With Type 2 Diabetes Hospitalized With COVID-19
Uploaded: 2021-07-02T18:00:00.000Z
Description: Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.

July 2, 2021

Video

Conference|ADA Scientific Sessions - American Diabetes Association Scientific Sessions

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.

Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.

During the discussion, Kosiborod addressed the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.